Schrödinger to Announce Third Quarter 2022 Financial Results on November 3 Oct 20, 2022 08:30AM
Schrödinger Hosts Platform Day Oct 6, 2022 07:10AM
Schrödinger to Host Platform Day on October 6, 2022 Sep 20, 2022 08:30AM
Schrödinger to Present at Citi’s 17th Annual BioPharma Conference Aug 31, 2022 08:30AM
Schrödinger Reports Inducement Grants To Newly Appointed Chief Financial Officer Aug 18, 2022 04:53PM
View Older Stories

Aug 18, 2022 07:01AM Schrodinger Inc. (SDGR) Appoints Geoffrey Porges as CFO
Aug 18, 2022 07:01AM Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
Aug 4, 2022 04:00PM Schrödinger Reports Second Quarter 2022 Financial Results
Jul 21, 2022 08:30AM Schrödinger to Announce Second Quarter 2022 Financial Results on August 4
Jun 28, 2022 07:01AM Schrodinger Inc. (SDGR) Granted FDA Clearance of IND for SGR-1505
Jun 28, 2022 07:00AM Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor
Jun 22, 2022 08:01AM Schrödinger Convenes Global Educators For Second Annual Educator’s Day
Jun 2, 2022 08:30AM Schrödinger to Present at Jefferies Healthcare Conference
May 19, 2022 07:00AM Schrödinger Announces Appointment of Arun Oberoi to Board of Directors
May 13, 2022 08:30AM Schrödinger to Present at Citi Biotech Virtual Co-Panel Day
May 4, 2022 04:01PM Schrödinger Reports First Quarter 2022 Financial Results
Apr 20, 2022 08:30AM Schrödinger to Announce First Quarter 2022 Financial Results on May 4
Apr 19, 2022 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 12, 2022 07:02AM Schrodinger Inc. (SDGR) Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at AACR
Apr 12, 2022 07:00AM Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting
Mar 17, 2022 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 8, 2022 04:35PM Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022
Feb 28, 2022 04:30PM Schrödinger to Present at Truist Securities Life Sciences AI Symposium - Biotech & Tools
Feb 24, 2022 04:01PM Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021
Feb 17, 2022 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 10, 2022 08:30AM Schrödinger to Announce Fourth Quarter and Full-Year 2021 Financial Results on February 24
Feb 8, 2022 08:30AM Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
Jan 20, 2022 04:00PM Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 18, 2022 06:46AM Schrodinger Inc. (SDGR) Acquires XTAL BioStructures for $6M
Jan 18, 2022 06:45AM Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
Jan 5, 2022 04:30PM Schrödinger to Present at H.C. Wainwright BioConnect Conference
Dec 21, 2021 07:02AM Schrodinger Inc. (SDGR) Announces CFO Retirement
Dec 21, 2021 07:00AM Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz
Dec 20, 2021 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Dec 13, 2021 05:18AM Schrodinger Inc. (SDGR) Announces Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program
Dec 11, 2021 09:05AM Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual Meeting
Nov 22, 2021 08:30AM Schrödinger to Participate in Five Upcoming Investor Conferences
Nov 18, 2021 07:00AM Schrödinger Awarded Grant to Accelerate Drug Discovery in Women’s Health
Nov 17, 2021 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2021 04:01PM Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company Update
Nov 9, 2021 08:30AM Schrödinger to Present at Jefferies London Healthcare Conference
Nov 4, 2021 09:05AM Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting
Oct 29, 2021 08:30AM Schrödinger to Host Conference Call to Discuss Third Quarter 2021 Financial Results
Oct 18, 2021 08:00AM Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
Oct 18, 2021 08:00AM Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
Oct 18, 2021 08:00AM Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
Oct 18, 2021 07:30AM Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 7, 2021 08:00AM MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program
Sep 22, 2021 08:30AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2021 08:31AM Schrödinger to Present at Four Investor Conferences in September
Aug 18, 2021 08:01AM Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 12, 2021 07:01AM Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update
Aug 4, 2021 07:30AM Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
Aug 4, 2021 07:30AM Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
Aug 4, 2021 07:30AM Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
View Older Stories